Immunotherapy company CEL-SCI Corporation (NYSE American: CVM) on Tuesday announced the successful commissioning of its Multikine manufacturing facility, a crucial step toward filing a Biologics License Application with the FDA and other regulators for marketing approval.
Originally built for the world's largest Phase 3 trial in head and neck cancer, the facility underwent expansion and upgrades for regulatory approval and commercial scale manufacturing. The commissioning adhered to industry standards, ISPE guidelines, ICH and regulatory requirements.
Designed to enhance the immune system's targeting of tumours, Multikine is administered in newly diagnosed head and neck cancer patients before standard care. CEL-SCI's unique approach, administering Multikine first, demonstrated statistically significant survival benefits in the final target population. The company plans to submit a proposed study protocol to the FDA in Q1 2024, aiming for FDA endorsement for a confirmatory clinical trial and exploring accelerated approval pathways.
Multikine has received FDA Orphan Drug designation for neoadjuvant therapy in head and neck squamous cell carcinoma.
CEL-SCI operates in Vienna, Virginia, and near/in Baltimore, Maryland.
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
Syndax Pharmaceuticals grants share purchase inducement awards to six new employees
Hippo Pharmacy launches fast, free delivery on orders over USD150
Polarean Imaging expands reach with Taiwanese distribution deal
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review